| pubmed-article:16610770 | pubmed:abstractText | Seattle Genetics is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. Phase II trials in patients with Hodgkin's disease, anaplastic large cell lymphoma, and cutaneous lymphoma have been conducted in the U.S. and Europe. | lld:pubmed |
